CAMBRIDGE, Mass, January 5, 2023 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage mRNA-immunotherapy company, today announced that Daniel Getts, Ph.D., CEO of Myeloid, will present at the 41st Annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023, in San Francisco, CA. The company is scheduled to present on Thursday, January 12, 2023, at […]
Myeloid Therapeutics Announces FDA Fast Track Designation for MT-101 for the Treatment of CD5+ Relapsed/Refractory PTCL CAMBRIDGE, Mass, October 27, 2022 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical-stage mRNA-immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to MT-101 in patients with refractory or relapsed CD5+ peripheral […]
Daniel Getts, CEO of Myeloid Therapeutics, wants to cure cancer. – – Daniel Getts, CEO of Myeloid Therapeutics, wants to cure cancer. He admits it’s a legitimately bold thing to say, but he has a strong belief that he will make an impact someday. When he walks into his office in Cambridge, Mass., he is […]